GBS Ventures appeared to be the VC, which was created in 1996. The company was established in Australia. The main department of described VC is located in the Melbourne.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the GBS Ventures, startups are often financed by Sofinnova Investments, QIC BioVentures, Prolog Ventures. The meaningful sponsors for the fund in investment in the same round are Uniseed Ventures, Delphi Ventures, Alloy Ventures. In the next rounds fund is usually obtained by Vivo Capital, Uniseed Ventures, Sofinnova Investments.
The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Nuon Therapeutics, NovaSys, CHF Solutions, Inc.. Among the most successful fund investment fields, there are Medical Device, Medical.
Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 investment rounds annually. The average startup value when the investment from GBS Ventures is 50-100 millions dollars. The common things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this GBS Ventures works on 11 percentage points less the average amount of lead investments. The higher amount of exits for fund were in 2017. The important activity for fund was in 2010.
This organization was formed by Brigitte Smith, Geoff Brooke. We also calculated 2 valuable employees in our database.
Related Funds
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Moximed | $40M | 16 Aug 2022 | Hayward, California, United States | ||
Moximed | $50M | 17 Mar 2017 | Hayward, California, United States | ||
Moximed | $50M | 16 Mar 2017 | Hayward, California, United States | ||
Moximed | $12M | 27 Jan 2016 | Hayward, California, United States | ||
Elastagen | $9M | 07 Jan 2016 | Sydney, New South Wales, Australia | ||
Moximed | $33M | 07 May 2015 | Hayward, California, United States | ||
$25M | 23 Sep 2014 | Irvine, California, United States | |||
$45M | 10 Apr 2014 | Preston, England, United Kingdom | |||
Neurovance | $6M | 03 Apr 2014 | Cambridge, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Moximed | $40M | 16 Aug 2022 | Hayward, California, United States | ||
Moximed | $50M | 17 Mar 2017 | Hayward, California, United States | ||
Moximed | $50M | 16 Mar 2017 | Hayward, California, United States | ||
Moximed | $12M | 27 Jan 2016 | Hayward, California, United States | ||
Elastagen | $9M | 07 Jan 2016 | Sydney, New South Wales, Australia | ||
Moximed | $33M | 07 May 2015 | Hayward, California, United States | ||
$25M | 23 Sep 2014 | Irvine, California, United States | |||
$45M | 10 Apr 2014 | Preston, England, United Kingdom | |||
Neurovance | $6M | 03 Apr 2014 | Cambridge, Massachusetts, United States |